Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies

Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study

(2012) Richard H Osborne et al.   Health and Quality of Life Outcomes

Operationalizing Value-Based Pricing of Medicines

(2012) Jon Sussex et al.   PHARMACOECONOMICS

Willingness to Pay for Improvements in Chronic Long-Acting Insulin Therapy in Individuals With Type 1 or Type 2 Diabetes Mellitus

(2011) Andrew Lloyd et al.   CLINICAL THERAPEUTICS

Health outcomes in economic evaluation: the QALY and utilities

(2010) S. J. Whitehead et al.   BRITISH MEDICAL BULLETIN

A comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetes

(2010) Michael Polster et al.   JOURNAL OF MEDICAL ECONOMICS

Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens

(2009) Jeremy Chancellor et al.   PHARMACOECONOMICS

A Predictive Model of Health State Utilities for HIV Patients in the Modern Era of Highly Active Antiretroviral Therapy

(2008) Teresa L. Kauf et al.   VALUE IN HEALTH

HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility?

(2007) Kirsten Howard et al.   HEALTH ECONOMICS

Welfarism vs. extra-welfarism

(2007) Werner B.F. Brouwer et al.   JOURNAL OF HEALTH ECONOMICS